The new normal: Opportunities and uncertainty are abundant

How should investors respond to the new normal that COVID-19 has forced investors to adapt? Jun Bei Liu of Tribeca Investment Partners discusses her thoughts.

Jun Bei Liu

The new normal: Opportunities and uncertainty are abundant

May 10, 2020
How should investors respond to the new normal that COVID-19 has forced investors to adapt? Jun Bei Liu of Tribeca Investment Partners discusses her thoughts.
Read Transcript

Originally coined by PIMCO boss Mohamed El-Erian, “the new normal” is a phrase we are hearing quite often in the investing world. This time around the term is referring to the new world order that investors are being forced to adopt post the COVID-19 crisis.

Many sectors have seen revenues collapse as a result of the lockdown. Reports of the millions of people around the world who have lost their jobs in just a few weeks certainly poses real questions: What will the new normal world look like? What level of earnings will return after the lockdown period? What shape will the recovery take? And what price should investors pay for such uncertainty?

There is no firm answer to these questions. No one sector will be affected in the same way and we are expecting extreme sectoral performance variation. Ultimately, investors will be willing to pay a premium for businesses that thrive and will punish those that lag.

As the world becomes awash with cheap liquidity, the gap between the good and bad performers will only become larger. Looking at what has happened at the sector level we can see where the opportunities are.

Sector performance converged during March except for healthcare, the meaningful outperformer. Discretionary, property trusts and infrastructure offered some of the worst returns.

One month on, with signs that lockdown will soon be lifted, investor rationality has returned. The previous underperformers were among some of the best stocks in April, despite most having withdrawn guidance and pointed to extreme uncertainty in the next three to six months.

If March was a panic selling month, then April was a panic buying month, as fear of missing out drove investors into anything that underperformed in March.

Of course, long-term returns will always be determined by the underlying fundamentals of a business. The earnings trajectory, strength of the business model, management execution track record and balance sheet capacity are some of the key determinants of a quality business.

Ultimately, we are in an unprecedented health crisis-induced global recession, and most businesses will be affected to some extent (even though some may not be as clear-cut at first glance). It’s crucial for management to respond quickly to manage costs and ensure ample liquidity.

Quality businesses that will thrive in this uncertain environment will be those that take advantage of the changing competitive dynamic.

V or U shaped?

We are expecting essential infrastructure-like sectors to experience more of a V-shaped recovery. Examples include Transurban, Atlas Arteria and Ramsay Health Care. Tollroad traffic will pick up as lockdown lifts, and Transurban has already commented on rising traffic in recent weeks. These companies will return to a more normalised earnings environment reasonably quickly.

The same can be said for Ramsay. The share price sharply underperformed from $80 to $50 on the government-mandated deferral in elective surgery, but the lifting of the restriction in the past few weeks will see earnings recover reasonably quickly and its raising has ensured ample balance sheet capacity to possibly take advantage of cheap global hospital assets.

Retailers should also see a quick earnings recovery after the consumer has been trapped indoors with limited options for entertainment. The opening of the shopping centres and retail stores will draw traffic, particularly with the government support and stimulus waiting to be spent.

There is, however, the risk that this pick-up in spending will be short-lived as rising unemployment is expected to hit consumer sentiment in three to six months.

In terms of a U-shaped recovery, the travel sector is a prime example, with most travel businesses in cash preservation mode and cash flow barely breaking even - even with balance sheet recapitalisations. Investors will have to put a lot of faith in management taking prudent measures with such uncertainty of demand.

Where to from here

Essentially, the new normal means lower interest rates for even longer, lower dividends and a tough earnings outlook for the near term, and perhaps dire macro data to hit the headlines.

But similar to what we demand of our portfolio companies, investors also need to adapt to this new world and be realistic about the treacherous path ahead, and be nimble in making investment decisions.

It’s important to remember that returns are made when others are fearful or greedy, and opportunities are in abundance for those that are looking. Do watch your step, however, in case a ditch is ahead.

Happy stock hunting.

 

Jun Bei Liu is the lead portfolio manager at Tribeca Investment Partners and a two-time conference manager.

 

Licensed by Copyright Agency. You must not copy this work without permission.

Originally coined by PIMCO boss Mohamed El-Erian, “the new normal” is a phrase we are hearing quite often in the investing world. This time around the term is referring to the new world order that investors are being forced to adopt post the COVID-19 crisis.

Many sectors have seen revenues collapse as a result of the lockdown. Reports of the millions of people around the world who have lost their jobs in just a few weeks certainly poses real questions: What will the new normal world look like? What level of earnings will return after the lockdown period? What shape will the recovery take? And what price should investors pay for such uncertainty?

There is no firm answer to these questions. No one sector will be affected in the same way and we are expecting extreme sectoral performance variation. Ultimately, investors will be willing to pay a premium for businesses that thrive and will punish those that lag.

As the world becomes awash with cheap liquidity, the gap between the good and bad performers will only become larger. Looking at what has happened at the sector level we can see where the opportunities are.

Sector performance converged during March except for healthcare, the meaningful outperformer. Discretionary, property trusts and infrastructure offered some of the worst returns.

One month on, with signs that lockdown will soon be lifted, investor rationality has returned. The previous underperformers were among some of the best stocks in April, despite most having withdrawn guidance and pointed to extreme uncertainty in the next three to six months.

If March was a panic selling month, then April was a panic buying month, as fear of missing out drove investors into anything that underperformed in March.

Of course, long-term returns will always be determined by the underlying fundamentals of a business. The earnings trajectory, strength of the business model, management execution track record and balance sheet capacity are some of the key determinants of a quality business.

Ultimately, we are in an unprecedented health crisis-induced global recession, and most businesses will be affected to some extent (even though some may not be as clear-cut at first glance). It’s crucial for management to respond quickly to manage costs and ensure ample liquidity.

Quality businesses that will thrive in this uncertain environment will be those that take advantage of the changing competitive dynamic.

V or U shaped?

We are expecting essential infrastructure-like sectors to experience more of a V-shaped recovery. Examples include Transurban, Atlas Arteria and Ramsay Health Care. Tollroad traffic will pick up as lockdown lifts, and Transurban has already commented on rising traffic in recent weeks. These companies will return to a more normalised earnings environment reasonably quickly.

The same can be said for Ramsay. The share price sharply underperformed from $80 to $50 on the government-mandated deferral in elective surgery, but the lifting of the restriction in the past few weeks will see earnings recover reasonably quickly and its raising has ensured ample balance sheet capacity to possibly take advantage of cheap global hospital assets.

Retailers should also see a quick earnings recovery after the consumer has been trapped indoors with limited options for entertainment. The opening of the shopping centres and retail stores will draw traffic, particularly with the government support and stimulus waiting to be spent.

There is, however, the risk that this pick-up in spending will be short-lived as rising unemployment is expected to hit consumer sentiment in three to six months.

In terms of a U-shaped recovery, the travel sector is a prime example, with most travel businesses in cash preservation mode and cash flow barely breaking even - even with balance sheet recapitalisations. Investors will have to put a lot of faith in management taking prudent measures with such uncertainty of demand.

Where to from here

Essentially, the new normal means lower interest rates for even longer, lower dividends and a tough earnings outlook for the near term, and perhaps dire macro data to hit the headlines.

But similar to what we demand of our portfolio companies, investors also need to adapt to this new world and be realistic about the treacherous path ahead, and be nimble in making investment decisions.

It’s important to remember that returns are made when others are fearful or greedy, and opportunities are in abundance for those that are looking. Do watch your step, however, in case a ditch is ahead.

Happy stock hunting.

 

Jun Bei Liu is the lead portfolio manager at Tribeca Investment Partners and a two-time conference manager.

 

Licensed by Copyright Agency. You must not copy this work without permission.

Disclaimer: This material has been prepared by Australian Financial Review, published on May 10, 2020. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

facebook
linkedin
All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No items found.
December 10, 2024

Professor Jane Butler: Sparking Hope for Spinal Cord Injuries

In this episode of the Hearts & Minds Podcast, we sit down with Professor Jane Butler to discuss her groundbreaking research into spinal cord injuries.

Read More
impact-podcasts
September 24, 2024

Asian Market Potential with Tom Naughton of Prusik

CIO Charlie Lancaster sits down with Tom Naughton, CIO of Prusik Investment Mgmt. Tom shares his investment philosophy, the opportunities and challenges in Asian markets, and how his 2023 conference stock pick, Swire Pacific (0019.HK), delivered an impressive 30% return.

Read More
investing
September 4, 2024

Building Hearts and Minds with Co-Founders Matthew Grounds and Guy Fowler

In this episode, co-founders Matthew Grounds AM and Guy Fowler OAM discuss their journey in building Hearts & Minds and its philanthropic model that has donated over $70 million to medical research.

Read More
investing
June 25, 2024

Navigating the Resource Sector with Jeremy Bond of Terra Capital

In this episode, we chat with Jeremy Bond, Founder of Terra Capital and HM1 Conference Fund Manager. Tune in for insights into the world of resource investments and the exciting opportunities that lie ahead.

Read More
investing
June 11, 2024

Prof. Nadia Badawi on Cerebral Palsy Breakthroughs and Neonatal Care

Dive deep into the groundbreaking work of Professor Nadia Badawi, an internationally recognised neonatologist and expert in Cerebral Palsy.

Read More
impact-podcasts
May 28, 2024

Investment Insights: Rikki Bannan on Top Picks and Trends

Join us for an engaging episode featuring Rikki Bannan, Portfolio Manager of IFM Investors and HM1 Conference Fund Manager. This episode explores Rikki's career journey, investment strategies, and her 2023 conference stock pick, Telix Pharmaceuticals (ASX.TLX).

Read More
investing
December 6, 2023

Peter Cooper talks building and instilling a culture of humility and excellence

In this episode, our guest is the renowned investor, Peter Cooper, founder and Chief Investment Officer of Cooper Investors (Core Fund Manager). A founding supporter of Hearts and Minds, Peter is a staunch advocate of our model and its philanthropic purpose, actively engaging in every facet of Hearts and Minds.

Read More
investing
November 28, 2023

Jun Bei Liu on her high conviction investment strategy

In this episode, HM1 Chief Investment Officer Charlie Lanchester is joined by Jun Bei Liu. Jun Bei is the Portfolio Manager of Tribeca’s Alpha Plus Fund and since taking over managing the Fund, she has quadrupled AUM.

Read More
investing
November 21, 2023

The world of rare genetic disease research

In this episode, we speak to Associate Professor Gina Ravenscroft. Gina is an Associate Professor in Neurogenetics at the Harry Perkins Institute of Medical Research in Perth. Her research interests are in rare genetic diseases, with a particular focus on neurogenetic diseases in babies and children.

Read More
impact-podcasts
November 14, 2023

Learn what makes a high conviction investment and how to avoid short-term noise

In this episode, our Core Fund Manager Magellan shares how they select top stocks for the HM1 portfolio.

Read More
investing
November 7, 2023

Delve into the world of kids critical care and trauma research

In thie episode, we are joined by Dr. Marino Festa, or Rino for short. He is the Medical Director of NSW Kids ECMO Referral Service and a senior specialist in Paediatric Intensive Care at Children’s Hospital at Westmead.

Read More
impact-podcasts
October 31, 2023

Where Regal's Phil King is searching for opportunities

HM1's CIO, Charlie Lanchester, talks to Phil King of Regal Funds about his passion for stocks, his ongoing search for opportunities, and some of the sectors he’s excited by right now. Phil King of Regal Funds, has been a tremendous supporter of Hearts & Minds since the beginning.

Read More
investing
October 24, 2023

Preventing recurrent miscarriages and birth defects

In this episode, CEO Paul Rayson is joined by renowned biomedical researcher Professor Sally Dunwoodie. Prof. Dunwoodie's groundbreaking work has revolutionised clinical practices and enabled genetic diagnostic tests worldwide. In 2017, her team achieved a double breakthrough with the potential to prevent recurrent miscarriages and various birth defects.

Read More
impact-podcasts
October 17, 2023

Nick Griffin on how he finds global winners

In this episode, CIO Charlie Lanchester chats with Nick Griffin, the founding partner and CIO of Munro Partners, one of HM1's Core Fund Managers. They go over his career to date, reflect on the lessons he’s learned, and trace the decisions that led to him starting Munro.

Read More
investing
October 10, 2023

How A/Prof Matt Call is teaching our body to kill cancer

In this episode, CEO Paul Rayson is joined by WEHI’s Associate Professor Matt Call to talk about his incredible research. Matt’s team teaches and trains the body's own immune cells to target and kill cancer cells.

Read More
impact-podcasts

No results found.

Please try a different search keyword or filter.